Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3001 to 3008 of 3008 results for all

  1. Record number of positive recommendations for blood cancer treatments

    Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.

  2. Heart failure patients to be remotely monitored by technology shown to cut hospitalisations by 50%

    Two technologies, HeartLogic and TriageHF, have been recommended in final diagnostic guidance.

  3. First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE

    For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.

  4. Emergency kits for people with adrenal insufficiency recommended to avoid hospital admission

    People with adrenal insufficiency should be given an emergency medical kit with potentially life-saving steroid injections, according to our new clinical guideline.

  5. New tests could spare people with early breast cancer from unnecessary chemotherapy

    More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.

  6. NICE publishes final draft guidance on Enhertu after commercial discussions conclude

    NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  7. NICE recommended personalised immunotherapy to treat blood cancer in children and young adults to be made routinely available on the NHS

    Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.

  8. NICE joins the shared commitment to public involvement in research

    Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.